Scientists discover brain's tau cleanup system for Alzheimer's

Researchers at UCLA Health and UC San Francisco have identified a natural defense mechanism in brain cells that helps remove toxic tau protein, potentially explaining why some neurons resist Alzheimer's damage better than others. The study, published in Cell, used CRISPR screening on lab-grown human neurons to uncover this system. Findings suggest new therapeutic avenues for neurodegenerative diseases.

Scientists have pinpointed a protein complex called CRL5SOCS4 that acts as a cleanup crew for tau, the toxic protein central to Alzheimer's disease and related dementias. Tau accumulation damages neurons, leading to cell death, but some brain cells show greater resilience. The research team employed CRISPRi, a gene-silencing tool, to test nearly every human gene's impact on tau buildup in neurons derived from human stem cells.

The screen revealed that CRL5SOCS4 tags tau with molecular markers, directing it to the cell's waste disposal system for breakdown. In brain tissue from Alzheimer's patients, neurons with elevated levels of CRL5SOCS4 components were more likely to survive amid tau presence. "We wanted to understand why some neurons are vulnerable to tau accumulation while others are more resilient," said Dr. Avi Samelson, first author and assistant professor of Neurology at UCLA Health, who led the work at UCSF. "By systematically screening nearly every gene in the human genome, we found both expected pathways and completely unexpected ones that control tau levels in neurons."

An additional finding linked mitochondrial stress—disruptions in the cell's energy producers—to the production of a harmful 25-kilodalton tau fragment, known as NTA-tau, detected in Alzheimer's patients' fluids. This fragment emerges under oxidative stress, impairing the proteasome's tau processing and altering protein clustering. "This tau fragment appears to be generated when cells experience oxidative stress, which is common in aging and neurodegeneration," Samelson noted.

The study highlights potential treatments, such as enhancing CRL5SOCS4 activity or safeguarding the proteasome during stress. It also identified other pathways, like UFMylation and membrane anchor enzymes, not previously linked to tau. Conducted with neurons carrying disease-causing mutations, the research was funded by the Rainwater Charitable Foundation/Tau Consortium and the National Institutes of Health. Researchers emphasize that further studies are required to develop therapies.

Articoli correlati

Scientific illustration depicting healthy and damaged tanycytes in the brain's third ventricle clearing tau protein in Alzheimer’s disease.
Immagine generata dall'IA

Study links tanycyte damage to reduced tau clearance in Alzheimer’s disease

Riportato dall'IA Immagine generata dall'IA Verificato

Researchers report that tanycytes—specialized cells lining the brain’s third ventricle—can help move tau protein from cerebrospinal fluid into the bloodstream, and that signs of tanycyte disruption in Alzheimer’s patient tissue may be associated with impaired tau removal. The findings, published March 5 in Cell Press Blue, are based on animal and cell experiments and analyses of human brain samples.

Researchers have uncovered how amyloid beta and inflammation may both trigger synapse pruning in Alzheimer's disease through a common receptor, potentially offering new treatment avenues. The findings challenge the notion that neurons are passive in this process, showing they actively erase their own connections. Led by Stanford's Carla Shatz, the study suggests targeting this receptor could preserve memory more effectively than current amyloid-focused drugs.

Riportato dall'IA

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Researchers are exploring CAR T-cell therapy to slow the advancement of amyotrophic lateral sclerosis (ALS) by targeting overactive immune cells in the brain. The approach aims to reduce neuron damage without curing the disease. Early studies suggest potential benefits for other neurodegenerative conditions as well.

Riportato dall'IA

Researchers at UCLA have identified senescent immune cells, dubbed 'zombie' cells, that accumulate in aging livers and contribute to fatty liver disease. By eliminating these cells in mice, the team reversed liver damage and reduced body weight, even on an unhealthy diet. The findings, published in Nature Aging, suggest similar mechanisms may drive human liver conditions.

Researchers at University College London have found that up to 93 percent of Alzheimer's cases may be linked to variants of the APOE gene, far more than previously estimated. The analysis, published in npj Dementia, also indicates that nearly half of all dementia cases could depend on this gene. The discovery underscores APOE as a key target for future treatments.

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta